Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-784.02%
operating margin TTM
-605.06%
revenue TTM
9.46 Million
revenue per share TTM
0.08$
valuation ratios | |
|---|---|
| pe ratio | -9.92 |
| peg ratio | 0.37 |
| price to book ratio | -9.96 |
| price to sales ratio | 78.52 |
| enterprise value multiple | -9.92 |
| price fair value | -9.96 |
profitability ratios | |
|---|---|
| gross profit margin | 90.34% |
| operating profit margin | -605.06% |
| pretax profit margin | -784.02% |
| net profit margin | -784.02% |
| return on assets | -65.15% |
| return on equity | 139.66% |
| return on capital employed | -59.6% |
liquidity ratios | |
|---|---|
| current ratio | 4.21 |
| quick ratio | 4.21 |
| cash ratio | 0.65 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 5.50 |
| operating cycle | 29.05 |
| days of payables outstanding | 882.72 |
| cash conversion cycle | -853.67 |
| receivables turnover | 15.50 |
| payables turnover | 0.41 |
| inventory turnover | 66.34 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.82 |
| debt equity ratio | -1.26 |
| long term debt to capitalization | 6.54 |
| total debt to capitalization | 4.85 |
| interest coverage | -5.60 |
| cash flow to debt ratio | -0.50 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.45 |
| cash per share | 6.64 |
| operating cash flow per share | -4.25 |
| free cash flow operating cash flow ratio | 1.05 |
| cash flow coverage ratios | -0.50 |
| short term coverage ratios | -7.97 |
| capital expenditure coverage ratio | -20.89 |
Frequently Asked Questions
When was the last time Cytokinetics, Incorporated (NASDAQ:CYTK) reported earnings?
Cytokinetics, Incorporated (CYTK) published its most recent earnings results on 05-05-2026.
What is Cytokinetics, Incorporated's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cytokinetics, Incorporated (NASDAQ:CYTK)'s trailing twelve months ROE is 139.66%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cytokinetics, Incorporated (CYTK) currently has a ROA of -65.15%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CYTK's net profit margin stand at?
CYTK reported a profit margin of -784.02% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CYTK's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.21 in the most recent quarter. The quick ratio stood at 4.21, with a Debt/Eq ratio of -1.26.